These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 24834836)
41. MicroRNAs in obesity-associated disorders. Abente EJ; Subramanian M; Ramachandran V; Najafi-Shoushtari SH Arch Biochem Biophys; 2016 Jan; 589():108-19. PubMed ID: 26416722 [TBL] [Abstract][Full Text] [Related]
42. 'Micro-managers' of hepatic lipid metabolism and NAFLD. Liu W; Cao H; Yan J; Huang R; Ying H Wiley Interdiscip Rev RNA; 2015; 6(5):581-93. PubMed ID: 26198708 [TBL] [Abstract][Full Text] [Related]
43. Effect of fructose and 3,5-diiodothyronine (3,5-T(2)) on lipid accumulation and insulin signalling in non-alcoholic fatty liver disease (NAFLD)-like rat primary hepatocytes. Gnocchi D; Massimi M; Alisi A; Incerpi S; Bruscalupi G Horm Metab Res; 2014 May; 46(5):333-40. PubMed ID: 24816759 [TBL] [Abstract][Full Text] [Related]
44. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome. Parafati M; Lascala A; Morittu VM; Trimboli F; Rizzuto A; Brunelli E; Coscarelli F; Costa N; Britti D; Ehrlich J; Isidoro C; Mollace V; Janda E J Nutr Biochem; 2015 Sep; 26(9):938-48. PubMed ID: 26025327 [TBL] [Abstract][Full Text] [Related]
45. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539 [TBL] [Abstract][Full Text] [Related]
46. De novo lipogenesis in health and disease. Ameer F; Scandiuzzi L; Hasnain S; Kalbacher H; Zaidi N Metabolism; 2014 Jul; 63(7):895-902. PubMed ID: 24814684 [TBL] [Abstract][Full Text] [Related]
47. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. Stachowicz A; Olszanecki R; Suski M; Wiśniewska A; Totoń-Żurańska J; Madej J; Jawień J; Białas M; Okoń K; Gajda M; Głombik K; Basta-Kaim A; Korbut R J Am Heart Assoc; 2014 Nov; 3(6):e001329. PubMed ID: 25392542 [TBL] [Abstract][Full Text] [Related]
49. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development. Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841 [TBL] [Abstract][Full Text] [Related]
50. Lipid transport biochemistry and its role in energy production. Ryan RO; van der Horst DJ Annu Rev Entomol; 2000; 45():233-60. PubMed ID: 10761577 [TBL] [Abstract][Full Text] [Related]
51. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135 [TBL] [Abstract][Full Text] [Related]
52. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Qi L; Liu S; Rifai N; Hunter D; Hu FB Atherosclerosis; 2007 May; 192(1):204-10. PubMed ID: 16781717 [TBL] [Abstract][Full Text] [Related]
53. Serotonergic Regulation of Hepatic Energy Metabolism. Park J; Jeong W; Yun C; Kim H; Oh CM Endocrinol Metab (Seoul); 2021 Dec; 36(6):1151-1160. PubMed ID: 34911172 [TBL] [Abstract][Full Text] [Related]
54. Insights into the roles of Apolipoprotein E in adipocyte biology and obesity. Jiang CL; Lin FJ Int J Obes (Lond); 2024 Sep; 48(9):1205-1215. PubMed ID: 38839985 [TBL] [Abstract][Full Text] [Related]
55. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Bolanos-Garcia VM; Miguel RN Prog Biophys Mol Biol; 2003 Sep; 83(1):47-68. PubMed ID: 12757750 [TBL] [Abstract][Full Text] [Related]
56. The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview. Tsilingiris D; Tzeravini E; Koliaki C; Dalamaga M; Kokkinos A Curr Obes Rep; 2021 Sep; 10(3):191-213. PubMed ID: 33840072 [TBL] [Abstract][Full Text] [Related]
57. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases. Sonnweber T; Pizzini A; Nairz M; Weiss G; Tancevski I Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360467 [TBL] [Abstract][Full Text] [Related]
58. Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer. Cheng C; Zhuo S; Zhang B; Zhao X; Liu Y; Liao C; Quan J; Li Z; Bode AM; Cao Y; Luo X Int J Biol Sci; 2019; 15(8):1654-1663. PubMed ID: 31360108 [TBL] [Abstract][Full Text] [Related]
59. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Li X; Wang H Cell Biosci; 2020 Dec; 10(1):140. PubMed ID: 33372630 [TBL] [Abstract][Full Text] [Related]
60. Role of Hepatokines in Non-alcoholic Fatty Liver Disease. Ke Y; Xu C; Lin J; Li Y J Transl Int Med; 2019 Dec; 7(4):143-148. PubMed ID: 32010600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]